Research & Development
Akebia Therapeutics Launches AkebiaCares, an Enhanced Patient Access Program for People with Chronic Kidney Disease
13 June 2019 - - US-based biopharmaceutical company Akebia Therapeutics, Inc. (NASDAQ: AKBA) has launched AkebiaCares, its enhanced patient access programme, the company said.
AkebiaCares provides patients, caregivers and health care providers with resources and important information to support greater access to Auryxia (ferric citrate).
Auryxia is the only oral iron tablet approved in the US to treat non-dialysis-dependent-chronic kidney disease adult patients for iron deficiency anemia, and dialysis-dependent CKD adult patients for hyperphosphatemia.
AkebiaCares offers services that include assisting patients and health care providers through the benefits investigation process, prior authorizations, appeals, copay assistance, and a patient assistance programme for financially eligible patients.
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease.
The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Auryxia (ferric citrate) was approved by the FDA on September 5, 2014 for the control of serum phosphorus levels in adult patients with CKD on dialysis and approved by the FDA on November 6, 2017 for the treatment of iron deficiency anemia in adult patients with CKD not on dialysis.
Iron Overload: Increases in serum ferritin and transferrin saturation were observed in clinical trials with AURYXIA in patients with chronic kidney disease on dialysis treated for hyperphosphatemia, which may lead to excessive elevations in iron stores. Assess iron parameters prior to initiating AURYXIA and monitor while on therapy.
Patients receiving concomitant intravenous iron may require a reduction in dose or discontinuation of IV iron therapy.
Risk of Overdosage in Children Due to Accidental Ingestion: Accidental ingestion and resulting overdose of iron-containing products is a leading cause of fatal poisoning in children under six years of age.
Advise patients of the risks to children and to keep Auryxia out of the reach of children.


Related Headlines